Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Body mass index (BMI) 18 to 36 kilograms per meter square (kg/m\^2), inclusive
For females of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during IgG administration and for 28 days after completion of IgG administration
For males: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm
You may not be if
Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the last study drug administration
Positive human immunodeficiency virus (HIV) test
Positive hepatitis B surface antigen or hepatitis B core antibody test
Positive hepatitis C virus antibody test
Regular alcohol consumption of \>8 drinks/week for females or \>12 drinks/week for males
Poor peripheral venous access
Major surgical procedure within 28 days prior to initiation of study treatment or anticipation of need for a major surgical procedure during the study
Known hypersensitivity to IgG or any of its components or to products made with IgG
History or presence of skin rash or other skin disorders
Inability to sense pain (e.g., peripheral neuropathy) or have a history of or have been diagnosed with a chronic pain syndrome
Infection or inflammation of the designated injection site (abdomen)
